DIA: Driving Insights to Action

Cures Within Reach at DIA 2017: Good Therapies at Reasonable Cost

Drug repurposing and reformulation leverage already expended costs for compounds that failed to reach the market for one disorder, to develop reformulated or repurposed drugs for a different condition in less time and with less cost. How will repurposing disrupt the current market? Where are the stress points in delivering repurposed products to patients? A special DIAmond panel discussion titled Drug Repurposing: Where Will It Take Us?, chaired by President and Chief Scientific Officer of Cures Within Reach Dr. Bruce Bloom, will explore this topic at our DIA 2017 Global Annual Meeting. “If you can repurpose a generic drug for some unmet medical need and you’re charging the same price for that drug as any other generic in use, you’re liable to be creating a good therapy at a very reasonable cost,” Dr. Bloom explains in this exclusive podcast. “If you’re able to do that, the net health care cost benefit is almost always significantly positive.” Register for our DIA 2017 Global Annual Meeting today!

EuroMeeting Co-Chair Envisions “Continuous Loop” from Bench to Bedside and Back

Dr. Susan Forda serves as Vice President of International Regulatory Affairs for Eli Lilly & Company Limited in the UK. She also contributes her expertise to various committees for the European Federation of Pharmaceutical Industries and Associations (EFPIA) and will serve as Co-Chair for DIA’s EuroMeeting 2017. In this interview with DIA Global Forum Editor Dr. Alberto Grignolo, Dr. Forda explains her perspective on health care and regulatory challenges facing Europe and on the EuroMeeting theme, From Bench to Bedside and Back. “This theme is really important at this juncture because we know that patients are increasingly taking an active role in their health care, and this connectivity is enabled by rapid improvements in technology – for instance, through the immediate availability of credible information in the palm of our hands,” she suggests. “The patient can provide access to knowledge that no one else does.” To learn more, register for our DIA EuroMeeting 2017 in Glasgow!

BfArM President: Real-World Data & Randomized Trials “Compatible, Complementary Tools”

Early access, real-world evidence and data generation, and Brexit are just a few of the high-level challenges facing European health care and regulatory systems. DIA’s EuroMeeting 2017 will discuss ways to approach these challenges in forums such as Major European Regulatory Science Challenges, which will be co-chaired by Dr. Karl Broich, President, Federal Institute for Drugs and Medical Devices in Germany (BfArM). “You will learn about early access to innovative products, that we have all our regulatory tools available. However, you will see as well that we have to improve our methodology and find ways into real-world evidence in addition to our usual randomized, controlled trials,” explains Dr. Broich. “They will complement each other in future clinical development plans, particularly if we are discussing early access for patients.” To learn more, register for our DIA EuroMeeting 2017 in Glasgow!